MX2011005269A - Composition for correcting malnutrition and decreasing obesity in children. - Google Patents
Composition for correcting malnutrition and decreasing obesity in children.Info
- Publication number
- MX2011005269A MX2011005269A MX2011005269A MX2011005269A MX2011005269A MX 2011005269 A MX2011005269 A MX 2011005269A MX 2011005269 A MX2011005269 A MX 2011005269A MX 2011005269 A MX2011005269 A MX 2011005269A MX 2011005269 A MX2011005269 A MX 2011005269A
- Authority
- MX
- Mexico
- Prior art keywords
- vitamin
- composition according
- nutritional composition
- provides
- obesity
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 208000008589 Obesity Diseases 0.000 title abstract description 37
- 235000020824 obesity Nutrition 0.000 title abstract description 37
- 208000002720 Malnutrition Diseases 0.000 title description 11
- 208000015380 nutritional deficiency disease Diseases 0.000 title description 11
- 235000000824 malnutrition Nutrition 0.000 title description 10
- 230000001071 malnutrition Effects 0.000 title description 10
- 230000003247 decreasing effect Effects 0.000 title description 2
- 235000016709 nutrition Nutrition 0.000 claims abstract description 34
- 229940088594 vitamin Drugs 0.000 claims abstract description 20
- 229930003231 vitamin Natural products 0.000 claims abstract description 20
- 235000013343 vitamin Nutrition 0.000 claims abstract description 20
- 239000011782 vitamin Substances 0.000 claims abstract description 20
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 19
- 239000011707 mineral Substances 0.000 claims abstract description 19
- 230000035764 nutrition Effects 0.000 claims abstract description 15
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 11
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- 235000010755 mineral Nutrition 0.000 claims description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 17
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 13
- 239000011701 zinc Substances 0.000 claims description 13
- 229910052725 zinc Inorganic materials 0.000 claims description 13
- 235000016804 zinc Nutrition 0.000 claims description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 235000006708 antioxidants Nutrition 0.000 claims description 12
- 229920001202 Inulin Polymers 0.000 claims description 10
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 10
- 229940029339 inulin Drugs 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- 239000011724 folic acid Substances 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 235000019155 vitamin A Nutrition 0.000 claims description 9
- 239000011719 vitamin A Substances 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 8
- 229930003268 Vitamin C Natural products 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 229940045997 vitamin a Drugs 0.000 claims description 8
- 235000021152 breakfast Nutrition 0.000 claims description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 6
- 239000010949 copper Substances 0.000 claims description 6
- 229910052802 copper Inorganic materials 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 239000011669 selenium Substances 0.000 claims description 6
- 229910052711 selenium Inorganic materials 0.000 claims description 6
- 235000011649 selenium Nutrition 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 235000013325 dietary fiber Nutrition 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- 230000004580 weight loss Effects 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 239000011785 micronutrient Substances 0.000 claims description 3
- 235000013369 micronutrients Nutrition 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003448 Vitamin K Natural products 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229910052750 molybdenum Inorganic materials 0.000 claims description 2
- 239000011733 molybdenum Substances 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 235000014786 phosphorus Nutrition 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000019168 vitamin K Nutrition 0.000 claims description 2
- 239000011712 vitamin K Substances 0.000 claims description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 229940046010 vitamin k Drugs 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims 1
- 239000011449 brick Substances 0.000 claims 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 235000021056 liquid food Nutrition 0.000 claims 1
- -1 polypropylene Polymers 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000012602 primary packaging material Substances 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- 230000007423 decrease Effects 0.000 abstract description 13
- 230000007812 deficiency Effects 0.000 abstract description 10
- 206010033307 Overweight Diseases 0.000 abstract description 9
- 208000017667 Chronic Disease Diseases 0.000 abstract description 4
- 210000000577 adipose tissue Anatomy 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 208000007502 anemia Diseases 0.000 abstract description 2
- 230000008131 children development Effects 0.000 abstract description 2
- 230000002641 glycemic effect Effects 0.000 abstract description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract description 2
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 18
- 230000036541 health Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 208000007683 Pediatric Obesity Diseases 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 208000016261 weight loss Diseases 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 206010048259 Zinc deficiency Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000003715 nutritional status Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 230000036186 satiety Effects 0.000 description 3
- 235000019627 satiety Nutrition 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010033929 calcium caseinate Proteins 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000018343 nutrient deficiency Nutrition 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000091577 Mexicana Species 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000008133 cognitive development Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000020802 micronutrient deficiency Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a composition that provides quality nutrition, and contributes to decrease overweight and obesity. The composition provides approximately 25% of a daily energy requirement, mostly from slow-release carbohydrates, therefore having a low glycemic index, also providing high biological value proteins, lipids with a high proportion of polyunsaturated fatty acids (90%) and vitamins and minerals required to correct their deficiency. The composition further contributes to eliminate anemia, enhances child development, prevents excessive accumulation of body fat and decreases the risk of obesity and chronic diseases. The composition may be used in School Lunch Programs aimed at improving nutrition and reducing obesity.
Description
COMPOSITION TO CORRECT MALNUTRITION AND DECREASE THE
OBESITY IN CHILDREN
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention is in the field of nutrition, energy metabolism and diseases related to nutrition. The invention discloses a food composition, which in addition to having an adequate balance of nutrients makes it suitable for use in children as a preventive measure in treatment programs and prevention of obesity.
STATE OF THE ART
Despite the enormous advances that Mexico has generally experienced in recent years, malnutrition and childhood obesity, there continue to be two public health problems that affect an increasingly large proportion of the population and therefore require solutions effective. Currently in our country 26% of the population of school age is overweight or obese, in addition to presenting high levels of malnutrition.
Since 1999, when the National Nutrition and Health Survey was conducted (Ensalud, 1999), we know that the deficiencies of some vitamins and minerals occur in a very high part of the population in Mexico and that they have important consequences on health. The most widespread nutritional deficiencies in Mexican children are iron, zinc, vitamin C and vitamin E. 41% of children under 12 are iron deficient, 34% have zinc deficiency 45% have deficiency of vitamin E and 35% have vitamin C deficiency. Children who are iron deficient suffer from anemia, decrease their ability to learn and significantly limit their development, zinc deficiency causes a decrease in the body's natural defenses, makes more susceptible to the child suffering from diseases, especially respiratory infections and diarrhea, it allows a greater deposition of fat in the body and delays growth. Deficiency of antioxidants such as vitamin C and vitamin E decrease the immune system's response capacity and increase the risk of suffering from hyperlipidemia and chronic diseases. In this way, children who are deficient in one or several of these or perhaps other vitamins and minerals generally have delays in their development and in their ability to resist some diseases but they are also more susceptible to depositing fat in their body, ie They are more susceptible to obesity. The fact that the deficiency of some vitamins and minerals contributes to obesity has been recently identified (García et al, 2009).
The most recent data at the national level, in the 2006 National Nutrition Survey, indicate that obesity and overweight occur in 14.7 of children under 5 years of age, 26.2% of children aged 5 to 11 years, 34.5% of children from 12 to 18 years old and 69.3 of adult women. The figures are extremely high, making Mexico one of the countries with the highest levels of obesity in the world. The biggest problem is that the trend of these figures is increasing, the prevalence of obesity increased from 18.4 to 26.2% (42.3% increase) in schoolchildren, from 24.9 to 34.5% (38.5% increase) in adolescent children and from 61 to 69.3% (13.6% increase) in adult women. It is urgent, therefore, to invent effective strategies that help to reduce obesity in children.
Obesity is a condition that is defined as the storage of excessive fat in the body, the problem is accentuated because the fat in the body causes insulin resistance which over time produces diabetes. Also an excess of fat causes that a greater amount of negative substances for the organism circulate in the blood, between these the cholesterol and the low density lipoproteins increase the probabilities of suffering hypertension and cardiovascular diseases. In this way, the overweight and obese individual is more likely to develop diabetes mellitus and cardiovascular disease. Some cancers such as prostate cancer in men or breast cancer in women also occur more frequently in obese people. Decreasing obesity will bring very important benefits to the health of individuals.
When obesity occurs in children increases the likelihood that the individual when an adult has obesity, this occurs because childhood obesity causes the number of adipose tissue cells multiply, which is the tissue where the excess fat is stored in the organism. The child who is obese creates conditions in his body so that when he is an adult it is easier for him to store fat and therefore be obese. It is very important to reduce childhood obesity if you want to reduce the adult population that will suffer from obesity, diabetes and cardiovascular disease in the coming years, which among other things will require very high sums of money, most likely unmanageable, to be able to try.
Mexico spends large sums of money on social programs to address the problems of nutrition and health of the population. Among these, the universal vaccination programs, the massive administration of vitamin A, the deworming programs and the greater availability of food thanks to the social development programs, have been efficient to reduce the percentage of children who presented malnutrition; However, deficiencies of vitamins and minerals prevail in different regions of the country and with greater incidence among the indigenous population, which is why a greater effort is needed to reduce regional disparities and ethnic origin.
One of the interventions made by the government of Mexico was the implementation of the school breakfast program. School breakfasts in the past may have been effective but today this is no longer the case because of the changes that society has had in terms of their lifestyle; Several health institutions agree that because of the inadequacy of their nutritional content, in addition to being inefficient in eradicating malnutrition problems, they have been precursors of another serious public health problem, childhood obesity.
A study conducted in 2000, in children aged 10 to 19 years, revealed that a high percentage of those who suffered from overweight and obesity, had abnormalities in their cholesterol, triglycerides and glucose, ie, that obesity was already manifesting its consequences on health at an early age The serious thing is that when these children reach the adult and productive age of life, they will have a high rate of diabetes, cerebrovascular accidents and, in later stages, they will have severe complications such as: blindness, kidney failure and amputations. his extremities, among others.
It is documented that more than 95% of childhood obesity is due to inadequate nutrition. In Mexico, the risk factor that is most associated with obesity in children is the change in dietary patterns with a high caloric value, and the decrease in the degree of physical activity (National Institute of Public Health. of Health and Nutrition 2006. Mexico, DF, pp: 94-97). In this aspect, according to studies by the National Institute of Nutrition and the Ibero-American University, many have contributed to the high rates of childhood obesity, the breakfasts that are taught in primary schools. In these breakfasts, milk, biscuits, legumes, and, to a lesser extent, vegetables and fruits prevail. These breakfasts, far from helping to fight malnutrition, have now raised obesity rates, since the breakfasts that are offered have a high caloric density as well as not providing the vitamins and minerals that are deficient in the population. In such a way that nowadays there are malnourished and obese children. According to findings from our research group, they have revealed a close interrelation between malnutrition and obesity, which is that obesity rates are increasing more rapidly in places where micronutrient deficiency is more prevalent. It is recognized that individuals with overweight or obesity have lower concentrations of some micronutrients, compared with individuals who have a normal weight.
This finding is important when you want to apply diet programs to control obesity.
To impact on the problem of obesity, therapeutic actions should be started at the moment of identifying a problem of overweight. The therapeutic approach of the child with obesity in the first level of attention must be preventive aimed at modifying the lifestyle and improving the feeding pattern. Overweight and obesity by themselves, do not require pharmacological treatment. However, obese children and adolescents with secondary metabolic disorders can be managed with pharmacological treatment, but this must be decided and monitored by a specialized doctor (Academia Mexicana de Pediatría, AC Conclusions of the National Meeting of Consensus on Prevention, Diagnosis and treatment of obesity in children and adolescents, 2002).
A decrease in energy intake through the application of a low calorie diet is effective to promote the loss of body fat and decrease body weight; However, in practice it is very difficult and even risky to undergo a diet low in calories, in addition to the risks of malnutrition that it implies, since the decrease in food consumption necessary to produce an energy deficit causes a decrease in the intake of proteins, vitamins and minerals whose consumption is essential to keep the body functioning properly. The deficient ingestion of some indispensable nutriment for a prolonged period can cause the deficiency of this nutriment which in turn will make the organism more susceptible to deposit more fat or generate a secondary metabolic disease. To avoid this, in the present invention,
developed a composition that at the same time provides quality nutrition, helps induce weight loss in obese children or maintain body weight in a healthy way. The composition was designed with the aim of providing approximately 25% of the daily energy required, coming from a greater proportion of slow-release carbohydrates, therefore low glycemic index, in addition to providing the vitamins and minerals that are essential for the proper development of the kids.
There is a prior art in the state of the art of the use of nutritional compositions and food replacements to improve nutritional status or induce weight loss (BUSPTO Application No. 10/361, 838; Gerhardt and Tasker (USPTO Application No. 10 / 519,657; Levine USPTO 7,030,092 B l; Grace et al US 6,426, 077 B l; Itchey USPTO 5,688,547; Hastings and collaborators USPTO 5,626,849; Bascom et al USPTO Sol. No. 1 1 / 32,341) None of the formulations described in the inventions previous presents an adequate nutritional profile to the Mexican population, also not focused on attacking both problems, ie malnutrition and maintenance or weight reduction.
The compositions included in the mentioned patents do not include the use of deficient minerals and vitamins in the Mexican population nor those whose deficiency is related to the deposition of fat, nor the use of antioxidants with antiatherogenic effect, nor the inclusion of soluble fibers such as inulin which helps to feel satiety and therefore consume less energy; In addition, the formulation compositions in the above patents were calculated to meet the
requirements of populations different from the Mexican one with deficiencies of nutrients and different states of health.
Specifically for use in children, the state of the art only shows a patent document where a nutritional composition for pediatric use is claimed (Mark et al., USPTO 5, 549,905). Said composition differs substantially from that claimed in our invention since it is directed to pediatric patients with altered absorption of certain nutrients and / or reduced gastrointestinal tolerance.
Currently in Mexico the multinational company Abbott commercializes a nutritional composition focused on children (Pediasure®), our formulation presents clear differences that provide important advantages for the application that we pretend children need to improve their nutritional status and at the same time prevent or treat an obesity problem The advantages of the invention are shown below:
a) A lower energy density < 200 kcal / dose versus 237 kcal / dose
b) Lower percentage of total energy (22% versus 35%) is provided by fats.
c) Higher percentage of energy is provided by carbohydrates (62% vs. 52%).
d) Higher content of soluble fiber
e) Better nutritional profile, according to the deficiencies of the Mexican infant population, in terms of vitamin A, folic acid, niacin, choline, vitamin E, vitamin C, copper and zinc.
The different composition of the present invention implies that it is used for a different purpose in a profile of individuals different from what currently exists. The formulations that currently exist could not achieve the results that are achieved with the developed invention.
DESCRIPTION OF THE INVENTION
The composition of the present invention comprises a nutritional composition for children between 1 and 11 years of age, which provides quality nutrition without inducing overweight and / or obesity. The composition provides protein of high biological value (calcium caseinate, whey protein concentrate), lipids with a high percentage of polyunsaturated fatty acids (90%), carbohydrates (maltodextrin, sucrose) very easily digested; besides the necessary vitamins for the best absorption of iron and synthesis of hemoglobin, minerals necessary for the infantile development, as well as antioxidants, vitamin A, C, E, Selenium and Zinc, that help to diminish the risk of obesity and chronic diseases, It contains inulin that contributes to satiety and prevents the increase of lipids in the blood and antioxidant vitamins that decreases the oxidation of fats and prevents cardiovascular disease.
It is a product that provides a large number of benefits, including:
»Contributes to the reduction of body fat
• Good bone health
o Reduction of risk of metabolic syndrome
• Improvement of the immune system
· Stimulation of cognitive development
»Improvement in the state of global nutrition
The present invention provides a formulation that contributes approximately 25% of the daily energy required. This supplement is added with 26 vitamins and minerals and is specially designed to improve the nutritional status and induce weight loss in obese children or maintain healthy body weight. In this formulation the micronutrients are selected from the group consisting of: Vitamin A, Vitamin D, Vitamin E, Vitamin K, Vitamin C, Vitamin B, Folic acid, Vitamin B6, Vitamin B12, Nicotinic acid, Biotin, Pantothenic acid, Phosphorus, Iodine, Iron, Magnesium, Copper, Zinc, Manganese, Selenium, Chromium and Molybdenum; The antioxidants are selected from vitamin E, vitamin C and selenium.
Unlike other formulations found in the state of the art, the composition of the present invention provides a healthy way to lose weight, since in addition to reducing energy intake, provides the vitamins and minerals found deficits in the population, and whose deficiency is highly related to the deposition of fat in the body. further
contain inulin whose main effect is to increase satiety, and to prevent the increase of lipids.
The composition provides adequate amounts of natural antioxidants such as vitamins A, C and E. The addition of one or more antioxidants increases the health benefits of the preparation of the present invention. These compounds help prevent cardiovascular diseases and certain types of cancer.
A very important vitamin, present in our invention is folic acid. Folic acid can be used in amounts ranging from 0.1 \ JQ to 5 mg per meal. It has been scientifically proven that folic acid reduces the formation of homocysteine, an atypical amino acid that damages the vascular system, causing death from cardiovascular disease. The composition of the present invention provides in a single shot 50% of the recommended daily intake of folic acid. The folic acid present in the preparation will help reduce the concentration of homocysteine in the blood of individuals, reducing the risk of a possible cardiovascular event.
The composition of the present invention provides 100% of the recommended daily intake (RDI) of vitamin A, which plays a very important role in the regulation of body weight and obesity through several of its metabolites.
A single shot of the composition of the present invention provides 60% of the RDI of vitamin D, which may have beneficial effects on body weight and insulin resistance since it is demonstrated that vitamin D deficiency, measured as 25-hydroxyvitamina D (Vitamin D3) has a high prevalence in obese subjects and is associated with an increased risk of insulin resistance.
Epidemiological studies have shown that low zinc intake and low plasma concentration are associated with an increase in the number and severity of infections, retarded growth, as well as an increase in the prevalence of obesity and other diseases. Zinc deficiency was identified as a risk factor for the development of central adiposity. A low intake of zinc is associated with a low activity of the enzyme superoxide dismutase, so that zinc deficiency increases oxidative stress and the inflammatory response in obese individuals.
Unlike other formulations do not consider Zinc as one of its essential components, the composition of the present invention provides in a single take of about 50% of the IDR zinc, so it is expected to have beneficial effects on the state of zinc nutrition obesity and its comorbidities.
The composition of the present invention provides about 300 pg of copper per serving. Copper is an essential component in many enzymatic systems essential for an adequate metabolism of carbohydrates and fats, so that ingestion at adequate levels causes beneficial effects on obesity and insulin resistance, in such a way, it is expected that the consumption of the composition of the invention has beneficial effects that contribute to the prevention of the development of diabetes, a risk to which individuals with obesity are exposed.
Raynor et al., (2005) analyzed the type of food consumed by a group of 2237 subjects of the National Weight Control Registry of the United States, who had lost approximately 32 kg and who maintained this loss of Weight for at least 6.1 years. The results showed that the weight control was produced thanks to the fact that more than 50% of the energy consumed by this group of people came from the carbohydrates and that also the energy that came from the consumption of fats was reduced. In this, the high consumption of low-fat foods (mainly cereals and foods with a high carbohydrate content) played a fundamental role. One strategy to induce weight loss is to decrease the energy coming from the fat by energy coming from carbohydrates. In this sense, the energy provided by the composition of the invention comes in more than 60% of the carbohydrates.
Unlike other formulations, the composition of the present invention contains as a dietary fiber source inulin, which is a soluble fiber that is not digested either in the stomach or in the small intestine so it arrives intact in the intestine thick where it is selectively fermented by the intestinal microflora of the colon (Roberfroid, 1999, aur et al., 2002). This means that it not only promotes optimal intestinal function but also acts as a prebiotic. A prebiotic is a nondigestible food ingredient that positively affects the host by selectively stimulating the growth and activity of endogenous bacteria in the colon. Inulin is thus a means to maintain the metabolic activity of lactobacilli and bifidobacteria, which inhibits the growth and development of harmful microorganisms in the colon. Consumption of inulin stimulates
the fermentation in the intestine and increases the absorption of minerals (Kaur et al.,
2002, Coudray, 2003).
In addition to this, some studies have shown that inulin in doses of 7 to 10 g per day has a beneficial effect on lipid metabolism, mainly in reducing the concentration of triglycerides in the blood (Brigenthi 2007)
The composition of the present invention provides between 1 and 3 g of fructoologosaccharides per portion, which produce beneficial effects on the health of the digestive system, immune function in addition to having a relevant role in the prevention of colon cancer and induce a better use of various minerals such as calcium and magnesium, key components for bones and teeth.
EXAMPLE 1
Qualitative-quantitative formula of the composition of the invention (Table 1) Content per 237 mL of reconstituidcequivalent product at 1 dose.
Product characteristics.
The composition of the invention was developed with the aim of providing a product with lower caloric index compared to those existing in the market, the above is achieved due to a low fat content. In addition to supplying proteins of high biological value; easily digested carbohydrates; It is also enriched with vitamins and minerals necessary for child development, as well as antioxidants (vitamin A, C, E, selenium and zinc), which help to reduce the risk of chronic diseases.
As a source of fiber, inulin is incorporated which is a soluble dietary fiber, which promotes intestinal movements, regulating intestinal transit. Stimulates the growth of the intestinal flora.
It has nutrients such as L-carnitine and taurine, which help ensure the metabolism of fats and bile salt formation respectively, also contains choline and inositol that improve cognitive functions such as learning and memory.
Product development.
When making the selection of the materials that make up the composition, special care was taken in the solubility and compatibility of the same, this in order to obtain a quality product that meets the purpose for which it was designed and meets the following criteria:
• Liquid with a volume of 237 mL.
• Nutritional profile.
• Stability
• Sensory evaluation (good consistency and pleasant taste).
The homogenization of the solids in the liquid system (water) is fundamental for the appearance and stability of the composition, which is why the solubility of each of the ingredients in the water and the use of a homogenizing equipment were considered. To avoid the phenomenon of sedimentation of solids and to improve the consistency of the product, xanthan gum is incorporated.
In addition, a manufacturing process is proposed in which the manner and order in which each ingredient is added is taken into consideration. Premixes of vitamins and minerals are prepared in order to improve and give uniformity to each of these components in the suspension.
One of the aspects that is most important in the preparation process is the incorporation of fat sources (vegetable oils) into an aqueous medium, so a careful selection and evaluation of emulsifiers that help to mix two immiscible liquids ( water and oil) and provide stability to our composition. The proposed method is the preparation of an emulsion formed by soy lecithin, a part of calcium caseinate in water and vegetable oils (previously treated with monodiglycerides and a compound emulsifier).
For the manufacturing process, 3 mixtures are prepared: mixture A containing the fatty solids, sample B containing the mixture of non-fatty solids and mixture C containing the milk protein. The mixture A is heated to 80 ° C and is incorporated into the mixture C. The emulsion formed by both mixtures is heated again to 65 ° C., then homogenized under pressure of 2200 lb / in2. The homogenized mixture is subjected to thermal treatment at 85 ° C for 30 seconds and mixture B and ascorbic acid are added. The mixture thus formed is filled with the amount of water necessary according to the batch size, and the quality measurements are made as pH, density, Brix degrees and total fat. This final mixture is homogenized at a pressure of 210 bar and finally subjected to pasteurization at 138 ° C for 4 seconds, for subsequent packaging.
Claims (15)
1. - A food composition that provides quality nutrition, and contributes to weight loss in obese children and maintain body weight in a healthy manner, characterized because it includes vitamins and minerals, natural antioxidants, a source of inulin-type dietary fiber, minus 26 vitamins and minerals, where the micronutrients are selected from the group consisting of: Vitamin A, Vitamin D, Vitamin E, Vitamin K, Vitamin C, Vitamin B, Folic acid. Vitamin B6, Vitamin B12, Nicotinic Acid, Biotin, Pantothenic Acid, Phosphorus, Yodc Iron, Magnesium, Copper, Zinc, Manganese, Selenium, Chromium and Molybdenum; The antioxidants are selected from vitamin E, vitamin C and selenium.
2. - The composition according to claim 1, characterized in that it comprises: from 0.5% to 10% by weight of the composition of vitamins and minerals I, from 0.1 to 10% by weight of the composition of natural antioxidants and from 1 to 30% by weight of the composition of a dietary fiber source of the inulin type.
3. - A food composition, according to claim 1 characterized in that at least 60% of the energy is provided by carbohydrates.
4. - A food composition, according to claim 1 characterized in that it provides between 3 and 10 g per dose of soluble dietary fiber.
5. - A nutritional composition according to claim 1, characterized in that the fiber is inulin. 6. - A formulation according to claim 1, characterized in that it provides between 1 and 3 g of FOS per dose. 7. - A nutritional composition according to claim 1, characterized in that it contributes in a single dose between 90% and 150% of the IDR of antioxidant vitamins such as vitamin C and tocopherol. 8. - A nutritional composition according to claim 1, characterized in that it provides in a single intake between 50% and 100% of the recommended daily intake of folic acid. 9. - A nutritional composition according to claim 1, characterized in that it provides in a single intake between 50 and 120% of the recommended daily intake of vitamin A. 10. - A nutritional composition according to claim 1, characterized in that it provides in a single dose between 50 and 100% of the recommended daily intake of vitamin D, preferably 60% of the RDI of vitamin D. eleven . - A nutritional composition according to claim 1, characterized in that it provides in a single intake between 40% and 10% of the recommended daily intake of zinc, preferably 50% of the zinc IDR. 2. A nutritional composition according to claim 1, characterized in that it provides in a single intake between 50 and 100% of the recommended daily intake of copper, preferably 70%. 13. - A nutritional composition according to claim 1, characterized in that it can be used in the individual feeding of children and in school breakfast programs. 14. - A nutritional composition according to claim 1, characterized in that it can be presented in powder to be mixed with water or some liquid food, or administered in ready-to-drink presentations. 15. - A nutritional composition according to claim 1, characterized in that the primary packaging material is selected from the following materials: can, tetra brick, polypropylene, glass, etc.
6. - A nutritional composition according to claim 1, characterized in that the nutrients and substances described are provided in a very concentrated manner in no more than 200 kcal per shot.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2011005269A MX363079B (en) | 2011-05-19 | 2011-05-19 | Composition for correcting malnutrition and decreasing obesity in children. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2011005269A MX363079B (en) | 2011-05-19 | 2011-05-19 | Composition for correcting malnutrition and decreasing obesity in children. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2011005269A true MX2011005269A (en) | 2012-11-19 |
| MX363079B MX363079B (en) | 2019-03-05 |
Family
ID=47891074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011005269A MX363079B (en) | 2011-05-19 | 2011-05-19 | Composition for correcting malnutrition and decreasing obesity in children. |
Country Status (1)
| Country | Link |
|---|---|
| MX (1) | MX363079B (en) |
-
2011
- 2011-05-19 MX MX2011005269A patent/MX363079B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX363079B (en) | 2019-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Balch | Prescription for nutritional healing | |
| US8298588B2 (en) | Dietary supplement containing alkaline electrolyte buffers | |
| CN102065709A (en) | Nutritional composition for bariatric surgery patients | |
| CN108391811A (en) | A kind of tumour full nutrition formula food and its application | |
| US20160136124A1 (en) | Administration of a food composition product | |
| Espinosa-Salas et al. | Nutrition: Macronutrient Intake | |
| CN108719977A (en) | A kind of breast cancer nutraceutical and preparation method thereof | |
| Godfrey et al. | Vitamins and minerals for health | |
| Rajesh et al. | Macro-and micronutrients in the development of food for babies and children | |
| MX2011005269A (en) | Composition for correcting malnutrition and decreasing obesity in children. | |
| Torkos | The Canadian encyclopedia of natural medicine | |
| Mudila et al. | Nutraceuticals for healthy sporting | |
| US9808441B2 (en) | Dietary supplement containing alkaline electrolyte buffers | |
| Sergeev et al. | Substantiation of the Use of Meat-Based Specialized Products in Nutrition of Patients With Arterial Hypertension | |
| Bronner | Nutritional aspects and clinical management of chronic disorders and diseases | |
| RU2849632C1 (en) | Protein-based reducing mixture | |
| KR20200058896A (en) | Composition for preventing malnutrition or improving nutritional status of patents after surgical procedures | |
| CN110558569B (en) | Transparent liquid nutritional composition comprising acidic whey derived proteins | |
| Senkottaiyan | Nutrition and the older diabetic | |
| Lachance | Food fortification with vitamin and mineral nutraceuticals | |
| CNC | Prescription for Nutritional Healing: A Practical A-to-Z Reference to Drug-Free Remedies Using Vitamins, Minerals, Herbs & Food Supplements | |
| CN117941826A (en) | A kind of complete nutrition protein powder for special medical use and preparation method thereof | |
| Young et al. | US Adult RDA: 400–1000 mg/Day Therapy Dose Range: 500–2000 mg/Day | |
| Sizer et al. | The Vitamins | |
| Duhan | SPORTS BEVERAGES |